

FseI
lacO3
lacO
M13R
pMB1 ori
pORT1aCMV rc
2269 bp
PCMV
M13F
BGH pA
Pme I (935)
HindIII (942)
Bam HI (960)
Eco RV (995)
Xba I (1022)
Pme I (1037)

FIG.1




FseI
lacO3
lacO1
M13R
pMB1 ori
pORT-RDD
2531 bp
PCMV
M13F
BGH pA
Hin dIII (1103)
RDD
hum urokinase
Pfo I (1227)

FIG.2



Comments for pVAX1®:
2999 bp

CMV promoter: bases 137-724
T7 promoter/priming site: bases 664-683
Multiple cloning site: bases 696-811
BGH reverse priming site: bases 823-840
BGH polyadenylation signal: bases 829-1053
Kanamycin resistance gene: bases 1226-2020
pUC origin: bases 2320-2993

FIG.3



pORT
pORT-RDD
Tumor volume (mm3)
1600
1400
1200
1000
800
600
400
200
0
0
2
4
6
8
10
12
14
days

FIG.4



pORT
pORT-RDD
Tumor volume (mm3)
500
450
400
350
300
250
200
150
100
50
0
0
1
2
3
4
5
6
7
Days

FIG.5



pORT
pORT-RDD
Tumor volume (mm3)
1800
1600
1400
1200
1000
800
600
400
200
0
0
2
4
6
8
10
12
14
days

FIG.6



pORT
pORT-RDD
V/V0
35
30
25
20
15
10
5
0
0
2
4
6
8
10
12
14
Days

FIG.7



2500
2000
1500
1000
500
0
Tumor volume (mm3)
TE-NaCl
25 µg
50 µg
100 µg
200 µg
400 µg
0
2
4
6
8
10
12
14
days

FIG.8



TE
pORT-RDD 1X
pORT-RDD 2X
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
2
4
6
8
10
12
14
16
18
20
days

FIG.9



TE vehicle
pORT-RDD
Tumor volume (mm3)
600
500
400
300
200
100
0
0
1
2
3
4
5
6
7
days

FIG.10



TE-NaCl
pORT-RDD
Blood vessel number
days
0
5
10
15
20
25
30
35
40
45
0
1
2
3
4
5
6
7

FIG.11



T- Lipo
BA015-VCC-004
% surviving cells
µg DNA
0
10
20
30
40
50
60
70
80
90
100
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2

FIG.12



T- Lipo
BA015-VCC-004
% surviving cells
100
90
80
70
60
50
40
30
20
10
0
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
µg DNA

FIG.13



% surviving cells
100
90
80
70
60
50
40
30
20
10
0
T- Lipo
BA015-VCC-004
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
µg DNA

FIG.14



Linear form
Supercoiled form

FIG.15



100
90
80
70
60
50
40
30
20
10
0
% living cells
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
µg DNA
T- Lipo
Batch 3
Batch 4

FIG.16



100
80
60
40
20
0
% living cells
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
µg DNA
T- Lipo
Batch 3
Batch 4

FIG.17



1400
1200
1000
800
600
400
200
0
Tumor volume (mm3)
0
1
2
3
4
5
6
7
8
9
days
Vehicle (n=10)
pORT-RDD (n=10)
pORT-RDD Lyoph (n=10)

FIG.18



2100
1800
1500
1200
900
600
300
0
Tumor volume (mm3)
vehicle
pORT-RDD
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Days

FIG.19



75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
Tumor volume (mm3)
0 1 2 3 4 5 6 7 8
Days

FIG.20